Helus Pharma CEO to Discuss Novel Neuropsychiatry Treatments at TD Cowen Summit
Event summary
- Helus Pharma CEO Michael Halstead to participate in fireside chat at TD Cowen's 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026.
- Company developing HLP003 (Phase 3) for major depressive disorder and HLP004 (Phase 2) for generalized anxiety disorder.
- Helus Pharma operates in Canada, the U.S., the U.K., and Ireland.
- HLP003 has received Breakthrough Therapy Designation from the FDA.
The big picture
Helus Pharma's participation in the TD Cowen summit highlights the growing interest in novel serotonergic agonists for mental health conditions. The company's focus on neuroplasticity aligns with broader industry trends toward mechanism-based treatments for depression and anxiety. The FDA's Breakthrough Therapy Designation for HLP003 underscores the potential of this therapeutic approach, though competition in the neuropsychiatry space remains intense.
What we're watching
- Clinical Progress
- The pace at which HLP003 advances through Phase 3 trials and potential FDA approval timeline.
- Market Positioning
- Whether Helus Pharma can differentiate its NSAs in the competitive neuropsychiatry market.
- Regulatory Dynamics
- How the FDA's Breakthrough Therapy Designation will impact HLP003's development and commercialization.
Related topics